Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Christy, Neil, Kowalski, A. E.
Format: Preprint
Veröffentlicht: 2024
Schlagworte:
Online-Zugang:https://arxiv.org/abs/2407.18206
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1866911967430574080
author Christy, Neil
Kowalski, A. E.
author_facet Christy, Neil
Kowalski, A. E.
contents We use the exact finite sample likelihood and statistical decision theory to answer questions of ``why?'' and ``what should you have done?'' using data from randomized experiments and a utility function that prioritizes safety over efficacy. We propose a finite sample Bayesian decision rule and a finite sample maximum likelihood decision rule. We show that in finite samples from 2 to 50, it is possible for these rules to achieve better performance according to established maximin and maximum regret criteria than a rule based on the Boole-Frechet-Hoeffding bounds. We also propose a finite sample maximum likelihood criterion. We apply our rules and criterion to an actual clinical trial that yielded a promising estimate of efficacy, and our results point to safety as a reason for why results were mixed in subsequent trials.
format Preprint
id arxiv_https___arxiv_org_abs_2407_18206
institution arXiv
publishDate 2024
record_format arxiv
spellingShingle Starting Small: Prioritizing Safety over Efficacy in Randomized Experiments Using the Exact Finite Sample Likelihood
Christy, Neil
Kowalski, A. E.
Econometrics
We use the exact finite sample likelihood and statistical decision theory to answer questions of ``why?'' and ``what should you have done?'' using data from randomized experiments and a utility function that prioritizes safety over efficacy. We propose a finite sample Bayesian decision rule and a finite sample maximum likelihood decision rule. We show that in finite samples from 2 to 50, it is possible for these rules to achieve better performance according to established maximin and maximum regret criteria than a rule based on the Boole-Frechet-Hoeffding bounds. We also propose a finite sample maximum likelihood criterion. We apply our rules and criterion to an actual clinical trial that yielded a promising estimate of efficacy, and our results point to safety as a reason for why results were mixed in subsequent trials.
title Starting Small: Prioritizing Safety over Efficacy in Randomized Experiments Using the Exact Finite Sample Likelihood
topic Econometrics
url https://arxiv.org/abs/2407.18206